Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Prestige Consumer Healthcare has a consensus “Hold” rating from six analysts, with one sell, three hold, and two buy recommendations. The average 12-month price target is $70.75.
• Institutional investors own 99.95% of PBH shares, with BlackRock recently establishing a stake worth approximately $370.2 million and several other funds increasing their holdings.
• The company exceeded quarterly expectations, reporting $0.98 in earnings per share versus the $0.89 consensus estimate and revenue of $265.71 million, up 6.5% year over year.

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have earned an average recommendation of "Hold" from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $70.75.

Several analysts recently weighed in on the company. Weiss Ratings lowered Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently added to or reduced their stakes in PBH. BlackRock Inc. bought a new stake in Prestige Consumer Healthcare in the second quarter worth about $370,187,000. Dimensional Fund Advisors LP grew its stake in shares of Prestige Consumer Healthcare by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company's stock valued at $158,414,000 after buying an additional 91,710 shares during the last quarter. Brandes Investment Partners LP grew its stake in shares of Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company's stock valued at $37,430,000 after buying an additional 292,744 shares during the last quarter. Norges Bank purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth approximately $36,954,000. Finally, Capital Research Global Investors raised its holdings in shares of Prestige Consumer Healthcare by 107.9% in the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company's stock worth $34,639,000 after buying an additional 291,425 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $44.92 on Friday. The company's 50-day moving average price is $50.56 and its 200-day moving average price is $52.68. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The company has a market cap of $2.13 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 1.41 and a beta of 0.33. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same quarter last year, the business posted $0.90 earnings per share. The firm's revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities research analysts forecast that Prestige Consumer Healthcare will post 4.56 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women's health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.

The company's brands include Clear Eyes, Dramamine, Monistat, Summer's Eve, Compound W, Chloraseptic, Luden's, BC, Goody's, Nix and Hydralyte, among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.